Rhumbline Advisers Bluebird Bio, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 271,090 shares of BLUE stock, worth $94,881. This represents 0.0% of its overall portfolio holdings.
Number of Shares
271,090
Previous 292,436
7.3%
Holding current value
$94,881
Previous $286,000
51.05%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding BLUE
# of Institutions
151Shares Held
63.4MCall Options Held
264KPut Options Held
428K-
Black Rock Inc. New York, NY15.4MShares$5.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.5MShares$3.67 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.68MShares$1.64 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$1.63 Million0.02% of portfolio
-
State Street Corp Boston, MA3.84MShares$1.34 Million0.0% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $27M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...